- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Pharmaceuticals Inc stock price live, this page displays NASDAQ ALNY stock exchange data. View the ALNY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alnylam Pharmaceuticals Inc real time stock price chart below.
What Is the Alnylam Pharmaceuticals Inc Stock Price Today?
The Alnylam Pharmaceuticals Inc stock price today is 320.53.
What Is the Stock Symbol for Alnylam Pharmaceuticals Inc?
The stock symbol for Alnylam Pharmaceuticals Inc is "ALNY."
What Stock Exchange Does Alnylam Pharmaceuticals Inc Trade On?
Alnylam Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Alnylam Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Alnylam Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALNY quote. (ISIN: US02043Q1076)
What Is the Alnylam Pharmaceuticals Inc Stock Price Today?
The Alnylam Pharmaceuticals Inc stock price today is 320.53.
What Is the Stock Symbol for Alnylam Pharmaceuticals Inc?
The stock symbol for Alnylam Pharmaceuticals Inc is "ALNY."
What Stock Exchange Does Alnylam Pharmaceuticals Inc Trade On?
Alnylam Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Alnylam Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Alnylam Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALNY quote. (ISIN: US02043Q1076)
320.53
-4.16(-1.28%)
Closed·
After Hours
291.42-29.11(-9.08%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
317.88
325.62
52 wk Range
205.87
333.70
ALNY Scorecard
Full Analysis
Net income is expected to grow this year
Unusual Post-Market activity
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
317.88325.62
52 wk Range
205.87333.70
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALNY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
332.06
Upside
+3.60%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Alnylam Company Profile
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer’s disease; and ALN-HTT02 that is in phase I clinical trial for Huntington’s disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals Inc SWOT Analysis
RNAi Pionee | Alnylam leads in RNA interference therapeutics, with a robust portfolio of approved drugs and a promising pipeline targeting rare diseases |
ATTR-CM Opportunity | Explore Alnylam's potential in the expanding ATTR-CM market, with Amvuttra poised to capture significant share in a multi-billion dollar arena |
Financial Trajectory | Analysts project profitability in 2025, with EPS estimates of $0.76. Price targets range from $250 to $500, averaging around $320 |
Competitive Edge | Delve into Amvuttra's differentiated label and Alnylam's strategic positioning against established players in the evolving ATTR-CM treatment landscape |
Alnylam Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- Q1 2025 EPS of -0.01 beat forecast of -0.93; revenue of $594.19M exceeded expectations of $588.75M
- Revenue grew 28% YoY; TTR franchise up 36% to $359M; rare disease franchise up 8% to $109M
- Stock fell 3.89% despite earnings beat; company maintains $2.6B cash and equivalents
- 36% YoY growth projected for TTR franchise; TRITON Centimeters Phase III study to start in H1 2025
- CEO reports strong start to 2025; CCO notes 80% of global addressable population remains untreated
Last Updated: 01-05-2025, 07:16 pm
Read Full TranscriptCompare ALNY to Peers and Sector
Metrics to compare | ALNY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALNYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −155.0x | −3.6x | −0.5x | |
PEG Ratio | −7.47 | −0.08 | 0.00 | |
Price/Book | 362.1x | 1.7x | 2.6x | |
Price / LTM Sales | 17.8x | 4.5x | 3.2x | |
Upside (Analyst Target) | 6.7% | 66.4% | 44.3% | |
Fair Value Upside | Unlock | −4.5% | 6.6% | Unlock |
Analyst Ratings
24 Buy
7 Hold
2 Sell
Ratings:
33 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 332.06
(+3.60% Upside)
Earnings
Latest Release
May 01, 2025
EPS / Forecast
-0.01 / -0.93
Revenue / Forecast
594.19M / 588.75M
FAQ
What Is the Alnylam (ALNY) Stock Price Today?
The Alnylam stock price today is 320.53.
What Stock Exchange Does Alnylam Trade On?
Alnylam is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Alnylam?
The stock symbol for Alnylam is "ALNY."
What Is the Alnylam Market Cap?
As of today, Alnylam market cap is 41.79B.
What Is Alnylam's Earnings Per Share (TTM)?
The Alnylam EPS (TTM) is -2.10.
When Is the Next Alnylam Earnings Date?
Alnylam will release its next earnings report on 30 Jul 2025.
From a Technical Analysis Perspective, Is ALNY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Alnylam Stock Split?
Alnylam has split 0 times.
How Many Employees Does Alnylam Have?
Alnylam has 2230 employees.
What is the current trading status of Alnylam (ALNY)?
As of 20 Jul 2025, Alnylam (ALNY) is trading at a price of 320.53, with a previous close of 324.69. The stock has fluctuated within a day range of 317.88 to 325.62, while its 52-week range spans from 205.87 to 333.70.
What Is Alnylam (ALNY) Price Target According to Analysts?
The average 12-month price target for Alnylam is USD332.0571, with a high estimate of USD500 and a low estimate of USD212. 24 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +3.60% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.